Medical honey for canine nasal intertrigo: A randomized, blinded, placebo-controlled, adaptive clinical trial to support antimicrobial stewardship in veterinary dermatology. by Gabrielle Brosseau, Nadia Pagé, Caroline de Jaham, Jérôme R E Del Castillo

Get full text

Feasibility of a pragmatic randomized adaptive clinical trial to evaluate a brief negotiational interview for harmful and hazardous alcohol use in Moshi, Tanzania. by Catherine A Staton, Kaitlyn Friedman, Ashley J Phillips, Mary Catherine Minnig, Francis M Sakita, Kennedy M Ngowi, Brian Suffoletto, Jon Mark Hirshon, Monica Swahn, Blandina T Mmbaga, Joao Ricardo Nickenig Vissoci

“…Intervention nurses believed Maintenance and sustainability of this 30-minute, low-cost intervention and adaptive clinical trial were feasible.<h4>Conclusions</h4>Our intervention and trial design are feasible and acceptable, have evidence of good fidelity, and did not show problematic deviations in protocol. …”
Get full text

Adaptive clinical trial of AZD7442 and SARS-CoV-2 vaccination in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus (RAPID-PROTECTION): protocol for a multicentre, interventional open-label, randomised controlled trial by Ernest Choy, Kerenza Hood, Emma Thomas-Jones, Eleanor Barnes, Keith Wilson, Christian H Ottensmeier, Debbie Harris, Adrian Hill, Mark Tuthill, Richard Adams, Catherine Porter, Katie Ewer, Sian Griffin, Rebecca Tangney, Joanne Euden, Shirley Pringle, Lawrence Raisanen, Ruby Ray, Lisette Sheena Nixon, Melanie Varley, Craig Bodman, Paola Cicconi, Vivien Dagley, Steven Knapper

Get full text

A Bayesian phase 2 model based adaptive design to optimise antivenom dosing: Application to a dose-finding trial for a novel Russell's viper antivenom in Myanmar. by James A Watson, Thomas Lamb, Jane Holmes, David A Warrell, Khin Thida Thwin, Zaw Lynn Aung, Min Zaw Oo, Myat Thet Nwe, Frank Smithuis, Elizabeth A Ashley

“…We propose a model based, Bayesian phase 2 type, adaptive clinical trial design for the characterisation of optimal initial antivenom doses in contexts where both efficacy and toxicity are measured as binary endpoints. …”
Get full text

Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy by Luca Mastrantoni, Giovanna Garufi, Giulia Giordano, Noemi Maliziola, Elena Di Monte, Giorgia Arcuri, Valentina Frescura, Angelachiara Rotondi, Armando Orlandi, Luisa Carbognin, Antonella Palazzo, Federica Miglietta, Letizia Pontolillo, Alessandra Fabi, Lorenzo Gerratana, Sergio Pannunzio, Ida Paris, Sara Pilotto, Fabio Marazzi, Antonio Franco, Gianluca Franceschini, Maria Vittoria Dieci, Roberta Mazzeo, Fabio Puglisi, Valentina Guarneri, Michele Milella, Giovanni Scambia, Diana Giannarelli, Giampaolo Tortora, Emilio Bria

“…Our model is freely available and can be used to enhance the stratification of BC patients receiving NACT, providing a framework for the development of risk-adapted clinical trials.…”
Get full text

Phase IV adaptive randomised clinical trials evaluating efficacy and cost-efficacy of pre-emptive pharmacogenetic genotyping strategies in the Spanish National Health System: iPHAR... by Xandra García-González, Alberto M Borobia, Antonio J Carcas, Miriam Estébanez, Montserrat Carmona, Irene García García, Francisco Abad-Santos, Luis A López-Fernández, Esther Cubo, Iñaki Imaz-Iglesia, Alicia Marín-Candón, Miriam Saiz-Rodríguez, Irene Taladriz-Sender, Pedro Arias, Rocío Rosas-Alonso, Enrique Seco-Meseguer, Stefan Stewart, Elena Diago-Sempere, María del Mar García Saiz, Emilio J Laserna-Mendieta, Ana M Peiró, Magí Farré, Consuelo Rodriguez-Jimenez, Judith Sanabria-Cabrera, Lucia Pedrosa, Ignacio Bernardino, Javier Guiijarro-Eguinoa, Arturo Gómez López De Las Huertas, Susana Martín-López, Olga Hladun Alvaro, Vicente Arrate, Ana Fries, Daniel Rodriguez Díaz, Fernando Marqués García, Núria Alonso Pedrol, Modesto M Maestre Muñiz, Leticia Rodríguez Alcolado, Carlos Ortiz-Bautista, Angela Remesal-Doblado, María Isabel Lucena, Zaida Salmón González, Inmaculada Coca-Prieto

“…The Spanish Consortium for the Implementation of Pharmacogenetics (iPHARMGx Consortium) addresses this by developing a clinical trial master protocol that will govern multiple nested adaptive clinical trials that compare genotype-guided treatments to standard care in specific drug–gene–population triads, asses their cost-efficacy and identify novel biomarkers through advanced sequencing techniques. …”
Get full text